Arpeggio Bio

Arpeggio Bio develops drugs targeting transcription factors using AI…

Y CombinatorSummer 2019ActiveHealthcareDrug Discovery and DeliveryBiotechGenomicsDrug discovery

What they do

Problem

Many important disease-driving transcription factors and other proteins are considered "undruggable," limiting effective treatments for cancers and other conditions.

Solution

The company uses AI and high-throughput RNA-sequencing to discover and develop drugs that target transcription factors such as NRF2, TEAD, and GPX4.

Who it's for

Pharmaceutical partners and clinical oncology teams developing and testing new therapeutics for patients, especially in oncology, rare disease, and inflammation.